.svg)
.jpg)
As more APIs present solubility, stability, and compatibility constraints, pharmaceutical companies are turning to pelletisation to achieve controlled release and multi-ingredient delivery within a single dosage form. This shift has strengthened the role of a capable pellets manufacturer in India in both development and commercial execution.
India has established itself as a strong global base for pellet manufacturing, supported by regulatory compliance, cost advantages, and process expertise. As discussed in our earlier blog, Understanding Pelletisation Techniques in Pharmaceutical Manufacturing: A Focus on the Indian Market, pelletisation continues to evolve as a critical capability for delivering consistent, high-performance formulations across both pharmaceuticals and dietary supplements.
For pharma companies seeking a reliable pellets manufacturer in India, understanding what separates a capable partner from a commodity supplier is the first step toward faster, more consistent product development.
Pellet-based systems enable a level of control that conventional dosage forms often struggle to achieve. Pellets in pharmacy are widely used for modified and controlled release applications, allowing precise modulation of drug release profiles and more consistent therapeutic outcomes. Their multiparticulate nature ensures uniform distribution in the gastrointestinal tract, which supports predictable absorption across patient populations.
This approach also addresses key formulation challenges. Pellets improve solubility and bioavailability for poorly water-soluble APIs by increasing surface area and enabling functional coatings. They also enhance stability, particularly for moisture-sensitive or oxidation-prone ingredients.
Another advantage lies in combining incompatible actives. Pellet systems allow separation of actives within a single dosage form, making it possible to deliver multi-ingredient therapies without compromising stability. This has expanded their use beyond pharmaceuticals into dietary supplements, where complex formulations require precise control over release and compatibility.
Leading manufacturers rely on a combination of proven and advanced pelletisation technologies to ensure consistency and scalability.
Extrusion-spheronisation: remains one of the most widely used techniques. It produces uniform, spherical pellets with narrow size distribution and supports high drug loading. This ensures consistent performance across batches and simplifies downstream processing.
Fluid bed systems: play a critical role in coating and layering. These systems allow drying, granulation, and coating within a single unit, improving efficiency and enabling precise control over release profiles. Functional coatings applied through fluid bed processing enable sustained, delayed, or enteric release, depending on therapeutic requirements.
Drug layering on inert starter cores: provides flexibility for low-dose or potent APIs. This method ensures accurate dose control and uniformity, particularly in multiparticulate systems.
Process optimisation remains essential across all technologies. Parameters such as moisture content, temperature, and spheronisation speed must be carefully controlled to maintain pellet size uniformity and mechanical strength. This level of control ensures scalability from pilot batches to commercial production without compromising quality.
Formulation expertise defines the performance of pellet-based systems. Leading players handle APIs with poor solubility and challenging physicochemical properties through tailored formulation strategies. Techniques such as polymer selection and coating optimisation help improve dissolution and absorption.
Manufacturers also design a range of release profiles, including immediate, delayed, and sustained release systems. This flexibility allows pharmaceutical companies to align formulations with therapeutic needs and dosing regimens.
Excipient selection plays a critical role in pellet performance. Compatibility between APIs and excipients must be carefully evaluated to prevent degradation or instability. This becomes even more important in multi-ingredient formulations, where interactions can impact efficacy.
Pelletisation also supports combination therapies within a single dosage form. By separating actives into different pellets, manufacturers enable delivery of incompatible ingredients while maintaining stability and controlled release. In dietary supplements, this approach is widely used, where combination of vitamins, minerals, botanicals and probiotics often involve s often involve incompatible ingredients that pelletisation can effectively isolate and co-deliver without compromising potency
Robust manufacturing infrastructure underpins successful pellet production. Leading manufacturers offer capabilities that span pilot-scale development to full commercial production, ensuring continuity across the product lifecycle.
Process control is critical at every stage. Pellet production involves multiple steps, including granulation, extrusion, spheronisation, drying, and coating. Each step requires precise monitoring to maintain batch consistency and avoid variability.
Advanced equipment and automation enhance reproducibility. Fluid bed processors, extruders, and coating systems must operate within tightly controlled parameters to ensure uniform pellet size and consistent release profiles.
Scale-up remains a key challenge in pellet manufacturing. Transitioning from pilot batches to commercial volumes requires a deep understanding of process dynamics. Variations in equipment or process conditions can affect pellet characteristics, for any pellets manufacturer in India targeting regulated export markets - US FDA, EU GMP, or WHO GMP - reproducibility at scale is not just a capability, it is a compliance requirement.
Manufacturers with strong scale-up expertise reduce the risk of batch failures and ensure that formulations perform consistently across different production scales.
Pelletisation supports a wide range of applications across oral solid dosage forms and dietary supplements. Pellets can be filled into capsules, compressed into MUPS tablets, or integrated into sachets and stick packs, offering flexibility in product design.
This versatility allows companies to create differentiated delivery formats that improve patient experience. Pellet-based systems offer better swallowability, reduced gastrointestinal irritation, and improved dosing flexibility, particularly in chronic therapies and pediatric formulations.
In nutraceutical applications, pelletisation enables precise control over multi-ingredient blends. It allows a combination of vitamins, minerals, botanicals, and probiotics within a single dosage form while maintaining stability and efficacy. This makes pellets particularly valuable for complex supplement formulations.
When pelletisation is embedded within CDMO workflows from formulation design through process development and commercial manufacturing.
Pharmaceutical and Nutraceutical companies split development across multiple partners. They streamline product development and reduce time-to-market with fewer errors and a more consistent product.
Pelletisation has become a critical capability in oral dosage and supplement development, enabling controlled release, improved bioavailability, and flexible formulation design. Selecting the right pellets manufacturer in India plays a key role in ensuring consistent product performance, regulatory compliance, and scalability.
ZIM Labs brings integrated expertise across pellet formulation, process optimisation, and commercial manufacturing, supporting pharmaceutical and nutraceutical partners in developing high-quality, differentiated products. With a strong focus on precision and scalability, it enables efficient translation of formulation strategies into commercially viable pellet-based solutions. Connect with ZIM Labs to explore how advanced pelletisation capabilities can support your next formulation or scale-up requirement.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
